Open AccessPhase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors
Author(s) -
Thomas J. Semrad,
Edward Jae-hoon Kim,
I-Yeh Gong,
Tianhong Li,
Scott Christensen,
Mili Arora,
Jonathan W. Riess,
David R. Gandara,
Karen Kelly
Publication year - 2021
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-021-04293-3
Subject(s) - irinotecan , medicine , tolerability , neutropenia , population , febrile neutropenia , response evaluation criteria in solid tumors , adverse effect , gastroenterology , pharmacokinetics , phases of clinical research , cancer , colorectal cancer , oncology , surgery , clinical trial , chemotherapy , environmental health
Aurora kinases are overexpressed or amplified in numerous malignancies. This study was designed to determine the safety and tolerability of the Aurora A kinase inhibitor alisertib (MLN8237) when combined with weekly irinotecan.